From L-R: Marc Tessier-Lavigne, Bob Nelsen, David Baker and Vik Bajaj

Ex­clu­sive: In $1B+ bet on AI, bio­phar­ma heavy­weights back new start­up to up­end drug R&D

A star-stud­ded mix of ven­ture cap­i­tal­ists and sci­en­tists, backed by more than a bil­lion dol­lars, is launch­ing an am­bi­tious biotech that aims to rein­vent drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Senior Associate - Life Science

Alexandria Real Estate Equities

Seattle, WA, USA